Adherence to angiotensin-converting enzyme inhibitors in incident chronic kidney disease patients

Changchun Wang, MS1, Wendy St. Peter, PharmD, FCCP1,2, Jiannong Liu, PhD1, Frank Daniels, BS1, David Gilbertson, PhD1, Allan Collins, MD, FACP1,2
1United States Renal Data System, Minneapolis Medical Research Foundation, 1,2University of Minnesota Twin Cities

Introduction

- Angiotensin-converting enzyme inhibitors (ACE-I) have been shown to slow the progression of kidney disease in hypertensive patients with diabetes or with proteinuria.
- Patient adherence to ACE-I is thought to be essential in slowing the progression of kidney disease, but the ACE-I adherence rate among chronic kidney disease (CKD) patients is unclear.
- The medication possession ratio (MPR), first introduced by Sclar et al. (1991), is one measure of medication adherence.
- The MPR is a continuous measure of adherence that allows assessment over multiple medication fill periods.
- Typically, a MPR threshold of 80% describes fairly consistent medication use.
- The goals of this study were to explore various methodologies for MPR calculation and to evaluate MPR as a measure of adherence to ACE-I in incident CKD patients.

Methods

- The MedStat MarketScan® Database (1999-2004) was used in this retrospective administrative data analysis.
- CKD patients were defined by at least 1 inpatient or 2 outpatient claims with CKD-related ICD-9-CM codes in each calendar year.
- Incident CKD patients (2000-2004) were selected if (1) they had CKD in current year, but did not have CKD in previous year; (2) their first CKD diagnosis date fell into a fee-for-service continuous enrollment period.
- ACE-I users were identified by at least (1) one ACE-I prescription claim after the first CKD diagnosis date; (2) a three-month enrollment period before the first ACE-I prescription claim.
- The MPR is defined as the sum of the days’ supply of medication divided by the number of follow-up days (Figure 1).
- The MPR was examined using various lengths of follow-up, a range of maximum allowable days of prescription gap; and the number of drug follow-up days as weight.

Results

- There were 63,356 incident CKD patients (2000-2004). Of those, 19,609 patients were on ACE-I.
  - 3,852 patients were <55 years old.
  - 4,766 patients were 56-64 years old.
  - 10,991 patients were ≥ 65 years of age.
- Using fixed follow-up periods from 6 to 24 months, the MPR decreased as follow-up time increased. For all patients, for example, it fell from 78.1 to 65.8% (Table 1 & Figure 2).
- For patients followed at least 12 months, without considering prescription gaps, the MPR decreased to 63.2% (Table 1 & Figure 2).
- Consideration of prescription gaps significantly impacted MPR calculation. By allowing a 90 day gap, for example, the MPR increased from 63.2% to 92.9% for all patients followed at least 12 months (Table 2 & Figure 3).
- Using the number of follow-up days as a weight versus no weight did not significantly affect the MPR (Table 2 & Figure 3).
- Regardless of methodology, adherence was better in patients age 56 and older than in younger patients (Figure 2 & 3).

Limitations

- The MarketScan® Database is composed of a large convenience sample of patients and not a random sample. Data may thus not be reflective of the broader U.S. CKD population.
- The MPR provides information on medication availability over defined periods of time, but does not shed light on the timeliness or consistency of prescription refilling.

Conclusions

- Assessment of ACE-I adherence based on MPR varied with methodology.
- The use of fixed follow-up periods provided a more realistic view of adherence; patients with short follow-up periods can bias MPR upwards when non-fixed periods are used.
- Older patients were more adherent. Patients younger than 56 should be targeted to improve adherence.

Figure 1. Distribution of MPR as a function of length of follow-up

Figure 2. Mean ACE-I MPR in incident CKD patients, by different fixed follow-up periods compared with at least 12 months follow-up

Figure 3. Mean ACE-I MPR in incident CKD patients, by different fixed follow-up periods or by at least 12 months of follow-up